Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;40(5):1470-7.
doi: 10.1097/CCM.0b013e3182416d7a.

Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study

Affiliations

Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study

Ednan K Bajwa et al. Crit Care Med. 2012 May.

Abstract

Objectives: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins") have anti-inflammatory properties and are associated with improved outcomes in critically ill patients. We investigated whether previous statin therapy affects outcomes in patients at risk for acute respiratory distress syndrome.

Design: Patients were followed-up for the primary outcome of acute respiratory distress syndrome and secondary outcomes of intensive care unit and 60-day mortality, organ dysfunction, and ventilator-free days in a secondary analysis of a prospective cohort study. Receipt of statin therapy was recorded. Propensity score matching was used to adjust for confounding by indication.

Setting: Intensive care units at a tertiary care academic medical center.

Patients: Critically ill patients (2,743) with acute respiratory distress syndrome risk factors.

Interventions: None.

Measurements and main results: Acute respiratory distress syndrome developed in 738 (26%) patients; 413 patients (15%) received a statin within 24 hrs of intensive care unit admission. Those who had received a statin within 24 hrs had a lower rate of development of acute respiratory distress syndrome (odds ratio 0.56; 95% confidence interval 0.43-0.73; p<.0001). After multivariate adjustment for potential confounders, this association remained significant (odds ratio 0.69; 95% confidence interval 0.51-0.92; p=.01). However, after propensity score matching, the association was not statistically significant (odds ratio 0.79; 95% confidence interval 0.57-1.10; p=.16). Statin use was not associated with reduced acute respiratory distress syndrome mortality, organ dysfunction, or ventilator-free days. Results of the study were presented in accordance with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.

Conclusions: Statin therapy at the time of intensive care unit admission was not associated with a lower rate of development of acute respiratory distress syndrome after matching for patient propensity to receive statins. Statin therapy was not associated with improvements in acute respiratory distress syndrome mortality, organ failure, or days free from mechanical ventilation.

PubMed Disclaimer

Conflict of interest statement

Dr. Malhotra has not disclosed any potential conflicts of interest.

Figures

Figure 1
Figure 1
Participant flow diagram depicting screening/enrollment process. ARDS, Acute Respiratory Distress Syndrome; ICU, intensive care unit.
Figure 2
Figure 2
Timing of development of acute respiratory distress syndrome (ARDS). ICU, intensive care unit.
Figure 3
Figure 3
The 28-day average daily multiple organ dysfunction score (MODS) from patients who had development of acute respiratory distress syndrome (ARDS) compared between patients who received statins before intensive care unit admission and patients who did not.

Comment in

Similar articles

Cited by

References

    1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–1349. - PubMed
    1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–1693. - PubMed
    1. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007;131:913–920. - PMC - PubMed
    1. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options. Am J Cardiol. 2005;96:53E–59E. - PubMed
    1. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: Pathophysiological role and clinical importance. Clin Chem Lab Med. 2010;48:1685–1691. - PubMed

Publication types

Substances